ArriVent BioPharma (AVBP) Earnings Date, Estimates & Call Transcripts → The Key to this $10 Trillion Tech Boom (From Porter & Company) (Ad) Free AVBP Stock Alerts $18.83 +0.17 (+0.91%) (As of 06/13/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Earnings SummaryUpcoming Earnings DateAug. 14EstimatedActual EPS (May. 8) -$0.70 Beat By $0.14 Consensus EPS (May. 8) -$0.84 Get ArriVent BioPharma Earnings AlertsEnter your email address below to receive the latest news and earnings results for AVBP and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueAVBP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AVBP Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. ArriVent BioPharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($1.25)($1.25)($1.25)Q2 20242($0.75)($0.64)($0.70)Q3 20242($1.22)($0.67)($0.95)Q4 20242($1.21)($0.70)($0.96)FY 20247($4.43)($3.26)($3.85)Q1 20251($0.73)($0.73)($0.73)Q2 20251($0.76)($0.76)($0.76)Q3 20251($0.79)($0.79)($0.79)Q4 20251($0.82)($0.82)($0.82)FY 20254($3.10)($3.10)($3.10)AVBP Earnings Date and InformationArriVent BioPharma last issued its earnings data on May 8th, 2024. The reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.14. ArriVent BioPharma has generated $0.00 earnings per share over the last year. Earnings for ArriVent BioPharma are expected to decrease in the coming year, from ($3.07) to ($3.13) per share. ArriVent BioPharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 14th, 2024 based off prior year's report dates.Read More ArriVent BioPharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/14/2024(Estimated)------- 5/8/2024Q1 2024($0.84)($0.70)+$0.14($0.70)-- ArriVent BioPharma Earnings - Frequently Asked Questions When is ArriVent BioPharma's earnings date? ArriVent BioPharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 14th, 2024 based off last year's report dates. Learn more on AVBP's earnings history. Did ArriVent BioPharma beat their earnings estimates last quarter? In the previous quarter, ArriVent BioPharma (NASDAQ:AVBP) reported ($0.70) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.84) by $0.14. Learn more on analysts' earnings estimate vs. AVBP's actual earnings. How much profit does ArriVent BioPharma generate each year? ArriVent BioPharma (NASDAQ:AVBP) has a recorded net income of -$69.33 million. AVBP has generated $0.00 earnings per share over the last four quarters. What is ArriVent BioPharma's EPS forecast for next year? ArriVent BioPharma's earnings are expected to decrease from ($3.07) per share to ($3.13) per share in the next year. More Earnings Resources from MarketBeat Related Companies: TG Therapeutics Earnings Rhythm Pharmaceuticals Earnings Indivior Earnings Geron Earnings Bausch Health Companies Earnings Deciphera Pharmaceuticals Earnings Janux Therapeutics Earnings Maravai LifeSciences Earnings Rocket Pharmaceuticals Earnings Vera Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple Stock All-Time Highs: Can AI Outweigh Earnings Jitters?CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry Shifts This page (NASDAQ:AVBP) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.